Oncology | Phase III Developments | SWITZERLAND

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

New Data At The ASCO20 Virtual Scientific Program Reflects Roche’s Commitment to Accelerating Progress in Cancer Care

Lead Product(s): Tiragolumab,Atezolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

Details:

First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with atezolizumab in patients with PD-L1-positive metastatic non-small cell lung cancer.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Roche's Tecentriq, on top of targeted drugs, stalls melanoma

Lead Product(s): Atezolizumab,Cobimetinib,Vemurafenib

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

In a phase 3 study presented at the American Association for Cancer Research meeting, adding Tecentriq to the targeted melanoma drugs lowered the risk of disease progression.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Tecentriq/Xtandi Combo Fails to Show OS Benefit, Halting Roche's PD-L1 Push into Prostate Cancer

Lead Product(s): Atezolizumab,Enzalutamide

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Roche conceded that Tecentriq failed to help prostate cancer patients live longer when added to Xtandi, Pfizer and Astellas’ mainstay androgen receptor antagonist.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Novartis Kymriah® Receives FDA Regenerative Medicine Advanced Therapy Designation in Follicular Lymphoma

Lead Product(s): Tisagenlecleucel

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah.

Sellas Life Sciences Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

SELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML

Lead Product(s): Galinpepimut-S

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

The Steering Committee will provide scientific oversight and guidance of the practical aspects of the ongoing REGAL study to evaluate galinpepimut-S (GPS) in patients with acute myeloid leukemia.

Polyphor

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Polyphor announces progress of the Phase III immuno-oncology program with balixafortide

Lead Product(s): Balixafortide,Eribulin Mesylate

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2020

Details:

If successful, balixafortide will be the first in class CXCR4 antagonist approved for a solid tumor indication widening the opportunities in the field of immuno-oncology.

FerGene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

FerGene to Present Bladder Cancer Data at 2020 ASCO

Lead Product(s): Nadofaragene firadenovec

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of li...

Lead Product(s): Atezolizumab,Bevacizumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe & effective treatments are available to patients.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Roche's checkpoint inhibitor fails pivotal urothelial cancer trial

Lead Product(s): Atezolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

Phase III IMvigor010 trial of Tecentriq as a post-surgery monotherapy didn’t hit its primary endpoint in muscle-invasive urothelial cancer. The primary endpoint was disease-free survival.

Sellas Life Sciences Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones

Lead Product(s): Galinpepimut-S,Pembrolizumab,Nivolumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway

Find

Find Oncology Drugs in Phase III Clinical Development in SWITZERLAND

Switzerland

A collaboration with SCORR Marketing

Product Type

Companies

F. Hoffmann-La Roche

New Data At The ASCO20 Virtual Scientific Program Reflects Roche’s Commitment to Accelerating Progress in Cancer Care

F. Hoffmann-La Roche

Roche's Tecentriq, on top of targeted drugs, stalls melanoma

F. Hoffmann-La Roche

Tecentriq/Xtandi Combo Fails to Show OS Benefit, Halting Roche's PD-L1 Push into Prostate Cancer

Novartis Pharmaceuticals Corporation

Novartis Kymriah® Receives FDA Regenerative Medicine Advanced Therapy Designation in Follicular Lymphoma

Sellas Life Sciences Group

SELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML

Polyphor

Polyphor announces progress of the Phase III immuno-oncology program with balixafortide

FerGene

FerGene to Present Bladder Cancer Data at 2020 ASCO

F. Hoffmann-La Roche

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of li...

F. Hoffmann-La Roche

Roche's checkpoint inhibitor fails pivotal urothelial cancer trial

Sellas Life Sciences Group

SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones